Athersys to Host Year-End 2021 Financial Results Call

New CEO, Daniel A. Camardo, and Management to Host Conference Call on March 15, 2022

CLEVELAND--(BUSINESS WIRE)-- Athersys, Inc. (Nasdaq: ATHX) will release its fourth quarter and full year 2021 financial results on Tuesday, March 15, 2022, after the close of the U.S. financial markets. Athersys’ new CEO, Daniel A. Camardo, along with the Company’s management team, will host a conference call at 4:30 p.m. Eastern Time that day to review the results. Mr. Camardo joined the company as CEO on February 14, 2022. Mr. Camardo comes to Athersys at a pivotal time to lead the Company’s transition to a commercial biopharmaceutical company and leader in cell therapy. Dan has over 25 years of commercial leadership experience and will lead the Company forward to complete development, and following approval, launch, market and commercialize MultiStem^® cell therapy for the treatment of serious conditions.

Details of the call be found below.

We encourage listeners to access the call using the webcast link above. If you would like to dial in using the phone, please register for the conference call ahead of time using the call registration link above. Once registered, you will receive an email containing the toll-free number, a direct entry passcode and a registrant ID.

A replay of the event will be available on the webcast link at www.athersys.com under the investors' section approximately two hours after the call has ended. Shareholders may also call in for on-demand listening approximately three hours after the completion of the call until 11:59 p.m. Eastern Time on March 22, 2022, by dialing (866) 813-9403 or (929) 458-6194 and entering the access code 084558.

About Athersys

Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem^® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization. Investors and others should note that we may post information about the Company on our website at www.athersys.com and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms. It is possible that the postings could include information deemed to be material information. Therefore, we encourage investors, the media and others interested in the Company to review the information we post on our website at www.athersys.com and on our social media accounts. Follow Athersys on Twitter at www.twitter.com/athersys. Information that we may post about the Company on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. You should not place undue reliance on forward-looking statements contained on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220215005294/en/

Ivor Macleod

Chief Financial Officer

Tel: (216) 431-9900

ir@athersys.com

Karen Hunady

Director of Corporate Communications and Investor Relations

Tel: (216) 431-9900

khunady@athersys.com

David Schull

Russo Partners, LLC

Tel: (212) 845-4271 or (858) 717-2310

David.schull@russopartnersllc.com

Peter Vozzo

ICR Westwicke

Tel: (443) 213-0505

peter.vozzo@westwicke.com

Source: Athersys, Inc.